# Iodine-125 brachytherapy for orbital-invasive low-grade myxofibrosarcoma of the maxillary sinus: a case report challenging conventional therapeutic paradigms

## TL;DR

A rare case of orbital-invasive myxofibrosarcoma was successfully treated with iodine-125 brachytherapy, offering better control and fewer side effects than traditional methods.

## Contribution

This case report presents iodine-125 brachytherapy as a novel, effective treatment for a rare and complex sarcoma.

## Key findings

- Iodine-125 brachytherapy achieved 12-month progression-free survival in a complex LGMFS case.
- The treatment caused no acute radiation toxicity and improved visual function and symptoms.
- It demonstrated superior precision and reduced systemic toxicity compared to conventional therapies.

## Abstract

Low-grade myxofibrosarcoma (LGMFS) is a rare subtype of soft tissue sarcoma, with an estimated incidence of approximately 0.18 cases per million population, accounting for about 0.6% of all soft tissue sarcomas. It is characterized by a high local recurrence rate and malignant potential. Orbital involvement secondary to maxillary sinus LGMFS represents an exceptionally rare occurrence. The management of such cases is complicated by anatomical complexity (e.g., proximity to optic nerve, lacrimal apparatus, and orbital vasculature) and limitations of conventional therapies, including radical resection combined with chemoradiation. In this anatomically complex case of recurrent Low-Grade Myxofibrosarcoma, iodine-125 brachytherapy achieved durable local control (12-month progression-free survival), demonstrating superior precision targeting and reduced systemic toxicity compared to conventional therapies. No acute radiation toxicity was observed, while facial swelling and eye pain were relieved with concurrent improvement in visual function.